The essential oil of Melaleuca alternifolia (tea tree oil) and its main component, terpinen-4-ol protect mice from experimental oral candidiasis

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 6, 2012, Pages 861-865

  Ninomiya, Kentaro ^a   Maruyama, Naho ^a,b   Inoue, Shigeharu ^a   Ishibashi, Hiroko ^a,c   Takizawa, Toshio ^a   Oshima, Haruyuki ^a   Abe, Shigeru ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b TEIKYO HEISEI UNIVERSITY   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Candida albicans; Essential oil; Melaleuca alternifolia

Indexed keywords

FLUCONAZOLE; PREDNISOLONE; TEA TREE OIL; TERPINEN 4 OL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL RESISTANCE; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CELL COUNT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FUNGAL STRAIN; FUNGAL VIABILITY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MOUTH CAVITY; NONHUMAN; OUTCOME ASSESSMENT; PROTECTION; SYMPTOM; THRUSH; TONGUE;

EID: 84861893624     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.861     Document Type: Article

References (21)

1. Odds FC. Candida and candidosis, A review and bibliography. Bailliere Tindale, London, pp. 4-129 (1988).
2. Meitner SW, Bowen WH, Haidaris CG. Oral and esophageal Candida albicans infection in hyposalivatory rats. Infect. Immun., 58, 2228-2236 (1990).
3. Lopez-Ribot JL, McAtee RK, Perea S, Kirkpatrick WR, Rinaldi MG, Patterson TF. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother., 43, 1621-1630 (1999).
4. D'Arrigo M, Ginestra G, Mandalari G, Furneri PM, Bisignano G. Synergism and postantibiotic effect of tobramycin and Melaleuca alternifolia (tea tree) oil against Staphylococcus aureus and Escherichia coli. Phytomedicine, 17, 317-322 (2010).
5. Hammer KA, Carson CF, Riley TV. Melaleuca alternifolia (tea tree) oil inhibits germ tube formation by Candida albicans. Med. Mycol., 38, 355-362 (2000).
6. Syed TA, Qureshi ZA, Ali SM, Ahmad S, Ahmad SA. Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream. Trop. Med. Int. Health, 4, 284-287 (1999).
7. Williams LR. Clonal production of tea tree oil high in terpinen-4-ol for use in formulations for the treatment of thrush. Complement. Ther. Nurs. Midwifery, 4, 133-136 (1998).
8. Abe S, Sato Y, Inoue S, Ishibashi H, Maruyama N, Takizawa T, Oshima H, Yamaguchi H. Anti-Candida albicans activity of essential oils including Lemongrass (Cymbopogon citratus) oil and its component, citral. Nippon Ishinkin Gakkai Zasshi, 44, 285-291 (2003), in Japanese.
9. Takakura N, Sato Y, Ishibashi H, Oshima H, Uchida K, Yamaguchi H, Abe S. A novel murine model of oral candidiasis with local symptoms characteristic of oral thrush. Microbiol. Immunol., 47, 321-326 (2003).
10. Maebashi K, Niimi M, Kudoh M, Fischer FJ, Makimura K, Niimi K, Piper RJ, Uchida K, Arisawa M, Cannon RD, Yamaguchi H. Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients. J. Antimicrob. Chemother., 47, 527-536 (2001).
11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts, Proposed standard. Document M27-P. National Committee for Clinical Laboratory Standards, Villanova, 1992.
12. Hisajima T, Maruyama N, Tanabe Y, Ishibashi H, Yamada T, Makimura K, Nishiyama Y, Funakoshi K, Oshima H, Abe S. Protective effects of farnesol against oral candidiasis in mice. Mycobiol. Immunol., 52, 327-333 (2008).
13. Hisajima T, Ishibashi H, Yamada T, Nishiyama Y, Yamaguchi H, Funakoshi K, Abe S. Invasion process of Candida albicans to tongue surface in early stages of experimental murine oral candidiasis. Med. Mycol., 46, 697-704 (2008).
14. D'Auria FD, Laino L, Strippoli V, Tecca M, Salvatore G, Battinelli L, Mazzanti G. In vitro activity of tea tree oil against Candida albicans mycelial conversion and other pathogenic fungi. J. Chemother., 13, 377-383 (2001).
15. Cox SD, Mann CM, Markham JL, Bell HC, Gustafson JE, Warmington JR, Wyllie SG. The mode of antimicrobial action of the essential oil of Melaleuca alternifolia (tea tree oil). J. Appl. Microbiol., 88, 170-175 (2000).
16. Sato T, Watanabe T, Mikami T, Matsumoto T. Farnesol, a morphogenetic autoregulatory substance in the dimorphic fungus Candida albicans, inhibits hyphae growth through suppression of a mitogen-activated protein kinase cascade. Biol. Pharm. Bull., 27, 751-752 (2004).
17. Brand C, Ferrante A, Prager RH, Riley TV, Carson CF, Finlay- Jones JJ, Hart PH. The water-soluble components of the essential oil of Melaleuca alternifolia (tea tree oil) suppress the production of superoxide by human monocytes, but not neutrophils, activated in vitro. Inflamm. Res., 50, 213-219 (2001).
18. Hart PH, Brand C, Carson CF, Riley TV, Prager RH, Finlay-Jones JJ. Terpinen-4-ol, the main component of the essential oil of Melaleuca alternifolia (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. Inflamm. Res., 49, 619-626 (2000).
19. Tisserand R, Balacs T. Essential oil Safety, a guide for health care professionals. Churchill Livingstone, New York, pp. 48-49 (1995).
20. Kang HY, Na SS, Kim YK. Effects of oral care with essential oil on improvement in oral health status of hospice patients. J. Korean Acad. Nurs., 40, 473-481 (2010).
21. Samejima K. Medical Aromatherapy. Medicus Shuppan Publishers, Osaka, pp. 36-38 (1999).